Optimer Pharma (OPTR) Presented New Data for Fidaxomicin's Phase 3
More News related to OPTR
- Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
- Oppenheimer Upgrades Optimer Pharmaceuticals (OPTR) to Outperform
- Morning Movers 11/12: NLST, HPJ, COMS, AMD, CAAS Higher; TRMS, NWPX, ATRN, BRCD, CDTI, GMCR Lower
- Optimer Pharmaceuticals Completes Enrollment in Second Fidaxomicin Phase 3 Clinical Trial in Patients With Clostridium difficile Infection
- Ladenburg Thalmann Downgrades Optimer Pharmaceuticals (OPTR) to Neutral
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the presentation of new data from fidaxomicin's North American phase 3 study at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia, PA.
Mark A. Miller, M.D., head of the Division of Infectious Diseases, Chair of the Infection Prevention and Control Unit at the Jewish General Hospital in Montreal, Quebec, Canada, presented results showing that fidaxomicin is associated with faster resolution of diarrhea. In patients with more pronounced diarrhea (ie. not resolving in the first 24 hours of therapy), fidaxomicin was associated with a faster time to resolution of diarrhea than vancomycin (79 hours vs. 105 hours, p=0.056). It is possible that decreasing the duration of diarrhea may have a direct impact on reducing the spread of CDI in healthcare facilities and lowering overall environmental spore contamination, thereby decreasing CDI rates and leading to earlier discharge of CDI patients from the hospital.
In another presentation, Kathleen M. Mullane, D.O., an investigator from the University of Chicago, Department of Medicine, Section of Infectious Diseases, in Illinois, presented data that indicated fidaxomicin may be a more effective therapy for CDI in patients requiring concomitant antibiotics. Treatment of CDI is often complicated by systemic infections requiring concomitant antibiotics. The analysis indicated that in patients receiving concomitant antibiotics, those treated with fidaxomicin versus vancomycin, had a significantly improved global cure rate (72% vs. 50%, p=0.022), lower CDI recurrence rate (40% vs. 23%, p=0.061), and higher clinical cure rate (87% vs. 77%, p=0.171).
Related Categories
Corporate NewsStocks Mentioned
-0.25Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
